Capstone Therapeutics Release: Apolipoprotein E Mimetic Peptide AEM-28 Granted Orphan Drug Designation for the Treatment of Homozygous Familial Hypercholesterolemia

Published: Dec 07, 2012

TEMPE, Ariz., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), today announced that LipimetiX Development, LLC ("LipimetiX") has received notice from the US Food and Drug Administration that AEM-28, an Apo E mimetic peptide drug candidate, has been granted Orphan Drug designation for the treatment of Homozygous Familial Hypercholesterolemia (HoFH).

Back to news